Literature DB >> 9062151

Identification of high-risk groups among node-positive patients with stage IB and IIA cervical carcinoma.

R A Samlal1, J van der Velden, M S Schilthuis, D González González, F J Ten Kate, A A Hart, F B Lammes.   

Abstract

The purpose of the present study was to identify a subset of high-risk patients among surgically treated node-positive patients with stage IB and IIA cervical carcinoma. From 1982 through 1991, 334 patients underwent radical hysterectomy for FIGO stage IB and IIA cervical carcinoma. In 68 patients pathological analysis of the surgical specimen revealed positive pelvic nodes. In this group, a Cox proportional hazard analysis was performed to examine the prognostic significance of clinicopathological variables. Only for adenocarcinoma (P = 0.002) and parametrium infiltration (P = 0.003) was evidence of an association with prognosis found. Based on these two factors, patients with positive pelvic nodes were categorized into a low-risk group (squamous cell carcinoma without parametrium infiltration, N = 33) and a high-risk group (squamous cell carcinoma with parametrium infiltration or adenocarcinoma, N = 34). The 5-year disease-specific survival in the low-risk group was 94% compared with 60% in the high-risk group (P = 0.003). For patients in the high-risk group, there is an urgent need for alternative adjuvant treatment to improve outcome.

Entities:  

Mesh:

Year:  1997        PMID: 9062151     DOI: 10.1006/gyno.1996.4576

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.

Authors:  Masahiro Kagabu; Tadahiro Shoji; Kazuyuki Murakami; Hideo Omi; Tatsuya Honda; Fumiharu Miura; Yoshihito Yokoyama; Hideki Tokunaga; Tadao Takano; Tsuyoshi Ohta; Dai Shimizu; Naoki Sato; Shu Soeda; Takafumi Watanabe; Hidekazu Yamada; Hideki Mizunuma; Nobuo Yaegashi; Satoru Nagase; Toru Tase; Toru Sugiyama
Journal:  Int J Clin Oncol       Date:  2016-01-19       Impact factor: 3.402

Review 2.  Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer.

Authors:  Noriaki Sakuragi
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

3.  Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer.

Authors:  Nicole D Fleming; Michael Frumovitz; Kathleen M Schmeler; Ricardo dos Reis; Mark F Munsell; Patricia J Eifel; Pamela T Soliman; Alpa M Nick; Shannon N Westin; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2014-11-18       Impact factor: 5.482

4.  Serum vascular endothelial growth factor: a prognostic factor in cervical cancer.

Authors:  Petra L M Zusterzeel; Paul N Span; Marja G K Dijksterhuis; Chris M G Thomas; Fred C G J Sweep; Leon F A G Massuger
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-15       Impact factor: 4.553

5.  Differing prognosis of cervical cancer patients with high risk of treatment failure after radical hysterectomy warrants trial treatment modification.

Authors:  Woo-Young Kim; Suk-Joon Chang; Ki-Hong Chang; Seung-Chul Yoo; Mison Chun; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

6.  The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.

Authors:  Georgia A McCann; Susanne K Taege; Christina E Boutsicaris; Gary S Phillips; Eric L Eisenhauer; Jeffrey M Fowler; David M O'Malley; Larry J Copeland; David E Cohn; Ritu Salani
Journal:  Gynecol Oncol       Date:  2012-11-05       Impact factor: 5.482

7.  Nedaplatin: a radiosensitizing agent for patients with cervical cancer.

Authors:  Seiji Mabuchi; Tadashi Kimura
Journal:  Chemother Res Pract       Date:  2010-09-21

8.  Loss of heterozygosity and copy number alterations in flow-sorted bulky cervical cancer.

Authors:  Sabrina A H M van den Tillaart; Wim E Corver; Dina Ruano Neto; Natalja T ter Haar; Jelle J Goeman; J Baptist M Z Trimbos; Gertjan J Fleuren; Jan Oosting
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

9.  The influence of number of high risk factors on clinical outcomes in patients with early-stage cervical cancer after radical hysterectomy and adjuvant chemoradiation.

Authors:  Soyi Lim; Seok-Ho Lee; Kwang Beom Lee; Chan-Yong Park
Journal:  Obstet Gynecol Sci       Date:  2016-05-13

10.  Risk model in stage IB1-IIB cervical cancer with positive node after radical hysterectomy.

Authors:  Zhilan Chen; Kecheng Huang; Zhiyong Lu; Song Deng; Jiaqiang Xiong; Jia Huang; Xiong Li; Fangxu Tang; Zhihao Wang; Haiying Sun; Lin Wang; Shasha Zhou; Xiaoli Wang; Yao Jia; Ting Hu; Juan Gui; Dongyi Wan; Ding Ma; Shuang Li; Shixuan Wang
Journal:  Onco Targets Ther       Date:  2016-05-27       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.